Stem Cell Research
Primary Outcome Measures: The primary outcome measure will be the difference from baseline in retinal nerve fiber layer (RNFL) thickness of the affected optic nerve, as determined by OCT, at 12 and 24weeks post LA treatment. [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ] Individual data will be assessed at the last study visit (six months post baseline). Group data cannot be assessed until all participants have exited the study.
Incomplete remission after an optic neuritis attack is not uncommon.
The primary aim of this open-label pilot trial is to estimate the treatment effect of 100 mg of oral minocycline twice daily for 90 days, initiated within 30 days of onset of ON, on functional and structural optic nerve recovery compared to no treatment. The primary outcome measure that will be used to measure optic nerve recovery is retinal nerve fibre layer (RNFL) thickness.
Primary Outcome Measures: Change in an objective measurement of spasticity between the pretreatment assessment and the 3- and 7-week assessments [ Time Frame: 7 weeks ] [ Designated as safety issue: Yes ]
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisThis study has been completed. Sponsor:
The recruitment status of this study is unknown because the information has not been verified recently. Verified April 2010 by University of Chicago. Recruitment status was Recruiting
This study is currently recruiting participants.
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares.
Multiple Sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system that destroys myelin, oligodendrocytes, and axons (14).
or (formerly called ) describes a medical condition in which the kidneys fail to adequately filter toxins and waste products from the blood.